MT2005-18: TRANSPLANTATION OF UMBILICAL CORD BLOOD FOR MYELOID LEUKEMIA PATIENTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究进一步研究了先前的研究（MT 2003 -01和MT 2004 -25），这些研究旨在确定特定的预备方案（环磷酰胺和氟达拉滨）是否可以创造一个环境，使输注的NK细胞能够生长并有效治疗复发性AML患者。本研究将采用完全成髓性制备方案（类似于我们的成髓性脐带血方案MT 2005 -10）测试NK细胞。我们正在专门研究标准UCB清髓性预备方案是否可以成功地与脐带血NK细胞和NK细胞前体细胞的输注相结合。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study furthers the research of previous studies (MT2003-01 and MT2004-25) which were to determine whether a specific preparatory regimen (clyclophosphamide and fludarabine) could create an environment in which infused NK cells can grow and effectively treat patients with relapsed AML. This study will test the NK cells with a fully myeloblative preparative regimen (similar to our myeloblative cord blood protocol MT2005-10). We are specifically studying whether standard UCB myeloblative preparatory regimen can be successfully combined with an infusion of cord blood NK cells and NK cell precursor cells.